GH vs. VCYT, NTRA, HIMS, RDNT, BTSG, SHC, OPCH, WGS, PRVA, and HTFL
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), Natera (NTRA), Hims & Hers Health (HIMS), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), GeneDx (WGS), Privia Health Group (PRVA), and Heartflow (HTFL). These companies are all part of the "healthcare" industry.
Guardant Health vs. Its Competitors
Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.
92.6% of Guardant Health shares are owned by institutional investors. 1.4% of Veracyte shares are owned by insiders. Comparatively, 6.1% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Veracyte has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Veracyte presently has a consensus price target of $40.90, indicating a potential upside of 16.30%. Guardant Health has a consensus price target of $65.86, indicating a potential upside of 1.76%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Guardant Health.
In the previous week, Veracyte had 2 more articles in the media than Guardant Health. MarketBeat recorded 9 mentions for Veracyte and 7 mentions for Guardant Health. Veracyte's average media sentiment score of 0.70 beat Guardant Health's score of 0.33 indicating that Veracyte is being referred to more favorably in the media.
Veracyte has a net margin of 5.50% compared to Guardant Health's net margin of -49.93%. Veracyte's return on equity of 6.07% beat Guardant Health's return on equity.
Veracyte has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
Summary
Veracyte beats Guardant Health on 11 of the 17 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
This page (NASDAQ:GH) was last updated on 10/8/2025 by MarketBeat.com Staff
